Netarsudil Lowers IOP, but When Should It Be Given?

COMMENTARY

Netarsudil Lowers IOP, but When Should It Be Given?

Shuchi B. Patel, MD

Disclosures

January 02, 2019

1

Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)

Serle JB, Katz LJ, McLaurin E, et al; ROCKET-1 and ROCKET-2 Study Groups Am J Ophthalmol. 2018;186:116-127

Study Summary

The double-masked ROCKET-1 and ROCKET-2 trials evaluated the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a newly available rho-kinase inhibitor and norepinephrine transporter inhibitor. These large-scale studies enrolling 1167 total patients primarily sought to establish noninferiority of netarsudil to timolol.

Eligible patients with either open-angle glaucoma or ocular hypertension underwent a washout period of all prestudy ocular hypotensive medications, during which their intraocular pressure (IOP) had to be > 17 mm Hg but < 27 mm Hg.

Patients were then randomly assigned to receive netarsudil 0.02% once daily, timolol 0.5% twice a day, or (ROCKET-2 only) netarsudil 0.02% twice daily. Diurnal IOP, as well as side effects including degree of hyperemia, were recorded at day 1, week 2, week 6, and month 3. Each study population had a mean age in the mid-60s, was predominantly female, and approximately 75% white and 25% black.

All three treatment groups produced statistically significant mean reductions from baseline IOP at all nine treatment time points over the 3-month efficacy assessment. Mean IOP ranged from 16.7 mm Hg to 18.2 mm Hg in the netarsudil once-daily group, 15.7 mm Hg to 17.6 mm Hg in the netarsudil twice-daily group, and 16.6 mm Hg to 17.7 mm Hg in the timolol twice-daily group. The mean decreases from baseline IOP ranged from 3.3 mm Hg to 4.6 mm Hg and 4.1 mm Hg to 5.4 mm Hg for the netarsudil once-daily and twice-daily groups, respectively, and from 3.7 mm Hg to 5.1 mm Hg for the timolol twice daily group.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....